Retatrutide 20mg Pen Lab Results — HPLC Purity Verification

The Janoshik panel for RET-20-C-2604-001 was a reverse-phase HPLC assay — the analytical standard for quantifying purity of synthetic peptides. The retatrutide fraction is separated from peptide-related impurities (truncated sequences, deletion variants, synthesis byproducts) on a C18 stationary phase, then quantified against a reference retention time for the parent peptide (LY-3437943, CAS 2381089-83-2). The reported 99.841% figure is the area-under-the-curve percentage for the parent peak, normalised against the sum of all peptide-related peaks in the chromatogram. Concentration was measured at 22.51 mg/mL, consistent with the pre-fill spec for the 20mg cartridge.

HPLC does not detect non-peptide content — water, salts, residual organic solvents from synthesis, or endotoxin. The pen line ships pre-formulated and pH-balanced rather than as a lyophilized solid, so the relevant verification is HPLC purity of the dissolved peptide. The fuller Janoshik panel — residual TFA, heavy metals (As, Cd, Pb, Hg), and bacterial endotoxin (LAL) — is published on the vial line (batch RET-20-V-2604-001) where the dry-fill workflow makes those additional panels load-bearing.

Retatrutide is a triple-receptor agonist — it engages GIP, GLP-1, and glucagon receptors with a single molecule. Triple-agonist potency is highly sensitive to sequence integrity: any truncation or deletion variant in the chain alters receptor binding for at least one of the three pathways, which makes HPLC purity verification meaningful, not cosmetic. The published Eli Lilly Phase 3 TRIUMPH-4 trial was conducted with reference-grade material; in-vitro research that aims to compare results to published trial data needs a comparable parent-peak fraction to be on the same baseline.

At 99.841% HPLC, batch RET-20-C-2604-001 is the highest-purity Retatrutide release Remy has published — ~0.6 percentage points above the 30mg pen (RETP002 at 99.262%) and ~0.1 above the vial line (RET-20-V-2604-001 at 99.741%). Inter-batch variation in that 0.1–0.6% range is normal for synthetic peptides and reflects analytical precision, not a systematic difference in synthesis quality. The remaining 0.159% is peptide-related material, not contamination by a different molecular entity.

Regional research pages now use this 20mg Pen batch as the public proof lane for country-specific queries: Buy Retatrutide Saudi Arabia | 20mg Pen COA, Buy Retatrutide Qatar | 20mg Pen COA, and Buy Retatrutide Lebanon | 20mg Pen COA. Each page keeps research-use retatrutide separate from Mounjaro or tirzepatide prescription-channel context.